The company
Editas Medicine, Inc.
EDIT · Nasdaq
Health CareGenomics & Gene EditingNot moving yetSynthetic Biology / TechBio
EDIT stood above a rising 150-day average in 19 of the last 52 weekly readings, and has been out of that trend for the last 4 weeks. It is 15.2% below that average now. Genomics & Gene Editing: 20% of its 5 stocks in an uptrend (−40 points in four weeks); Health Care: 26% (−10 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 4
- Industry in uptrend
- 20% -40 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $199K
- Officials’ trades on record
- 17
- Institutions holding
- 207 (+12)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 19 of 52 weeks.
20 Apr – 19 Oct
Genomics & Gene Editing: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
1 Nov 2024 – 1 Oct 2026
Open-market buys above the line and sales below, in dollars.
Congress and officials
17 disclosed lines: House 14, Senate 3, executive 0; 5 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Daniel S. Goldman House: U.S. House ClerkNY10 | sold | $1k–$15k | 10 Apr 2023filed 19 May 2023 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | sold | $1k–$15k | 14 Apr 2021filed 1 May 2021 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | sold | $1k–$15k | 2 Mar 2021filed 1 Apr 2021 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | boughtjoint | $1k–$15k | 17 Nov 2020filed 1 Dec 2020 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | soldjoint | $1k–$15k | 1 May 2020filed 31 May 2020 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | soldjoint | $1k–$15k | 27 Apr 2020filed 9 May 2020 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | bought | $1k–$15k | 27 Jan 2020filed 22 Feb 2020 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | boughtjoint | $1k–$15k | 9 Jan 2020filed 22 Feb 2020 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | bought | $1k–$15k | 23 Dec 2019filed 2 Jan 2020 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | boughtjoint | $1k–$15k | 9 Dec 2019filed 14 Dec 2019 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | boughtjoint | $1k–$15k | 22 Nov 2019filed 14 Dec 2019 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | boughtjoint | $1k–$15k | 19 Nov 2019filed 14 Dec 2019 |
Insiders
Buy orders, 12 months0
Sale orders, 12 months14
Buyers · sellers0 · 3
| Who | Did | Shares | Traded |
|---|---|---|---|
| Gilmore Neil O'NeillCEO | sold | 5,124at $3.04 | 3 Sep 2026filed 4 Sep 2026 |
| Linda BurklyEVP, CHIEF SCIENTIFIC OFFICER | sold | 709at $3.04 | 3 Sep 2026filed 4 Sep 2026 |
| Amy ParisonSVP, Chief Financial Officer | sold | 453at $3.04 | 3 Sep 2026filed 4 Sep 2026 |
| Amy ParisonSVP, Chief Financial Officer | sold | 678at $2.58 | 3 Aug 2026filed 5 Aug 2026 |
| Linda BurklyEVP, CHIEF SCIENTIFIC OFFICER | sold | 4,928at $2.67 | 28 Jul 2026filed 29 Jul 2026 |
| Linda BurklyEVP, CHIEF SCIENTIFIC OFFICER | sold | 731at $2.70 | 3 Jun 2026filed 5 Jun 2026 |
| Gilmore Neil O'NeillCEO | sold | 15,380at $2.70 | 3 Jun 2026filed 5 Jun 2026 |
| Amy ParisonSVP, Chief Financial Officer | sold | 464at $2.70 | 3 Jun 2026filed 5 Jun 2026 |
| Linda BurklyEVP, CHIEF SCIENTIFIC OFFICER | sold | 749at $2.02 | 3 Mar 2026filed 4 Mar 2026 |
| Amy ParisonSVP, Chief Financial Officer | sold | 474at $2.02 | 3 Mar 2026filed 4 Mar 2026 |
| Gilmore Neil O'NeillCEO | sold | 5,394at $2.02 | 3 Mar 2026filed 4 Mar 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Holders207+12 on the quarter
New · exited38 · 26
Reported value$383.4M
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| TCG Crossover Management, LLCnew · filed 14 Aug 2026 | 11,111,111$36.0M | +11,111,111 |
| BlackRock, Inc.added · filed 7 Aug 2026 | 10,589,990$34.3M | +1,326,678+14.3% |
| RA CAPITAL MANAGEMENT, L.P.new · filed 14 Aug 2026 | 8,889,000$28.8M | +8,889,000 |
| Commodore Capital LPnew · filed 14 Aug 2026 | 8,889,000$28.8M | +8,889,000 |
| ADAR1 Capital Management, LLCnew · filed 14 Aug 2026 | 8,889,000$28.8M | +8,889,000 |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 6,141,336$19.9M | +1,936,967+46.1% |
| Paradigm Biocapital Advisors LPnew · filed 14 Aug 2026 | 5,586,625$18.1M | +5,586,625 |
| Opaleye Management Inc.added · filed 14 Aug 2026 | 3,861,930$12.5M | +1,934,933+100.4% |
| VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 2026 | 3,598,339$11.7M | +449,769+14.3% |
| Woodline Partners LPnew · filed 14 Aug 2026 | 3,555,497$11.5M | +3,555,497 |
31 Mar 2023 – 30 Jun 2026
News
Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemiamanilatimes.net · 8 Oct 2026Editas Medicine, Inc.: Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemiafinanznachrichten.de · 8 Oct 2026Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officerfinanznachrichten.de · 8 Sep 2026
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.